OBIO
Orchestra BioMedยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
OBIO Profile
Orchestra Biomed Holdings, Inc.
A therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases
Healthcare Equipment and Supplies
05/25/2020
08/04/2020
NASDAQ Stock Exchange
70
12-31
Common stock
150 Union Square Drive, New Hope, Pennsylvania 18938
--
Orchestra BioMed Holdings, Inc., incorporated in Delaware on May 25, 2020, is a biomedical innovation company that accelerates the development of high-impact technologies for patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's collaborative business model focuses on establishing strategic partnerships with leading medical device companies to drive the successful commercialization of the products they develop globally. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy for the treatment of hypertension, a significant risk factor for death worldwide, Virtue Sirolimus AngioInfusion Balloon (SAB) is used to treat atherosclerotic artery disease, which is the leading cause of death worldwide. Orchestra BioMed has entered into a strategic partnership with Medtronic, one of the largest medical device companies in the world, to develop and commercialize BackBeat CNT for the treatment of high blood pressure in patients indicated by pacemakers, and Virtue SAB for the treatment of arterial disease.
